Lazard Asset Management
UNCY icon

Lazard Asset Management’s Unicycive Therapeutics UNCY Stock Holding History

Lazard Asset Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,575
Closed -$55K – 2334
2025
Q2 		$55K Buy
+11,575
New +$71.6K ﹤0.01% 1993

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lazard Asset Management's UNCY Position: Q3 2025 in Review

Lazard Asset Management sold out of Unicycive Therapeutics (UNCY) in Q3 2025, closing a stake of 11,575 shares — an estimated $55K sold.

Lazard Asset Management first reported a position in UNCY in Q2 2025 and held it in 1 quarter. The position peaked at $55K in Q2 2025. 30 funds tracked by Wall St. Rank hold UNCY as of Q3 2025.

  • Lazard Asset Management reported no remaining Unicycive Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 11,575 Unicycive Therapeutics shares in Q3 2025, an estimated $55K.
  • Lazard Asset Management first reported a position in Unicycive Therapeutics in Q2 2025 and held it in 1 quarter.
  • Lazard Asset Management's Unicycive Therapeutics position peaked at $55K in Q2 2025.
  • 30 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.